Kornimate/medical-research-clean huggingface dataset:
examination of the pressure ulcers in intensive care patients.

Conditions: Pressure Ulcer; İntensive Care; Nurse's Role

Summary: a pressure sore was localized skin and/or subcutaneous tissue injury, usually caused by pressure alone or a combination of shear and pressure, at bony prominences. pressure sores, which are an indicator of the quality of health care, increase mortality, morbidity and cost. pressure ulcers are the most common problem in intensive care patients and should be prevented. in the literature, the incidence of pressure ulcers in intensive care patients is between 1-59.9%. a pressure sore is a localized injury to the skin and/or underlying soft tissue, usually over a bony prominence or associated with medical or other devices. this injury occurs when intense and/or prolonged pressure or pressure is accompanied by shear. soft tissue tolerance to pressure and shear; temperature and humidity can affect nutrition, perfusion, concomitant conditions, and condition of soft tissue. this study was carried out to determine the prevalence of pressure ulcers and influencing factors in patients hospitalized in the 3rd level intensive care unit of a university hospital. design: it is a descriptive, prospective, observational type study. materials and methods: the sample of the study consisted of 176 patients aged 18 years and above, 24 hours after hospitalization in the intensive care units of a university hospital. patient information form and braden scale for predicting pressure ulcer risk, glasgow coma scale were used to collecting data. statistical package in statistical analysis for the social sciences 20.0 program was used.

due to the renovation initiated in the intensive care units, the work was started in november 2019, but the working time was extended due to the covid 19 pandemic that developed immediately after. the sample of the study consisted of patients who met the inclusion criteria and accepted participation, among the patients who were hospitalized on wednesday, which was determined as the middle of each week, between november 2019 and february 2021 in the 3rd-level intensive care units of a university hospital. data collection: "personal information form" prepared by the researcher as a result of the literature review for data collection, "braden scale for predicting pressure ulcer risk" for evaluating pressure ulcers, "glasgow coma score" for evaluating patient's consciousness status, and ulcer used by national pressure ulcer advisory panel and european pressure ulcer advisory panel staging classification was used.

Eligibility criteria:
inclusion criteria: * over 18 years old * hospitalized in the 3rd step intensive care unit * being hospitalized for at least 24 hours * no pressure ulcers on the first hospitalization exclusion criteria: * hospitalization time not exceeding 24 hours

Keywords: intensive care unit pressure ulcer risk factors prevalence
music in urgent and emergent settings

Conditions: Musculoskeletal Pain

Summary: the purpose of this study is to study the impact of live preferential music on the patient perception of pain and management of pain syndromes in the ed.

the purpose of this study is to study the impact of live preferential music on the patient perception of pain and management of pain syndromes in the ed. this study follows a prospective experimental design where patients will be assigned to two groups: one that receives the music intervention and one that does not receive music intervention.

Eligibility criteria:
inclusion criteria: 1. age: ≥18 2. chief complaint of musculoskeletal pain 3. gender: male or female 4. ethnicity: any 5. physical ability: any 6. language: english 7. cognitive skill/education: grade 2 reading level or above 8. physically and cognitively able to participate in study procedures exclusion criteria: 1. patients who are unable to participate in the informed consent process 2. prisoners
longitudinal study on glaucoma surgery using xen® gel stent

Conditions: Glaucoma; Glaucoma, Open-Angle; Glaucoma, Angle-Closure; Glaucoma, Primary Open Angle

Summary: to evaluate the safety and efficacy of the xen® gel stent in mild to moderate glaucoma patients undergoing glaucoma surgery.

to evaluate the safety and efficacy of the xen® gel stent in mild to moderate glaucoma patients undergoing glaucoma surgery. follow-up period is 2 years.

Eligibility criteria:
inclusion criteria: * mild to moderate glaucoma patients * have given written informed consent * aged 18 years or older of either sex exclusion criteria: * patients not able to understand the character of the study * participation in other clinical research within the last 4 weeks * patients with end-stage glaucoma * patients with glaucoma surgery done before
advance-d: antitachycardia pacing (atp) delivery for painless implantable cardioverter defibrillator (icd) therapy

Conditions: Tachycardia, Ventricular; Ventricular Fibrillation

Summary: the purpose of this study is to estimate and quantify the difference in efficacy of two sequences of atp therapies (burst 15 pulses, 88% versus burst 8 pulses, 88%) during an episode of spontaneous rhythms classified as fast ventricular tachycardia (fvt) via ventricular fibrillation (vf) in patients who have a class i or ii a indication for icd implantation, and thus to promote the "painless" therapy aspect of icd treatment and improve quality of life outcomes for patients.

main objective: compare \& quantify efficacy of two different sequences of burst atp strategies for the termination of ventricular tachycardia (with cycle lenght (cl) of 240ms-320ms) from baseline to 12 months post randomisation in patients who are treated with atp -8 pulses, 88% versus patients who are treated with atp -15 pulses, 88% secondary objectives: * estimate the efficacy of atp in successfully treating fvt episodes for patients in primary and secondary prevention * estimate acceleration rate or degeneration of atp therapy for treating spontaneous fvt episodes in the atp 15 vs 8 arm * compare the likelihood of syncopal events associated with spontaneous fvt episodes * estimate the percent reduction in number of shocks delivered per patient for treating spontaneous fvt episodes * evaluate different possible predictors of atp success: vt rate, underlying disease, anti-arrhythmic drugs (aad), infarct zone, etc.

Eligibility criteria:
inclusion criteria: * icd indications (class i-ii a) according to the guidelines (patient with coronary artery disease \[cad\] or non-cad in primary or secondary icd prevention) * patients have been implanted with a medtronic marquis family icd capable of atp for fvt via vf exclusion criteria: * patient's life expectancy less than 1 year due to a non-cardiac chronic disease * patient on heart transplant list which is expected in \< 1 year * patient's age less than 18 years * icd replacements and upgrading (single chamber \[sc\] icd® dual chamber \[dc\] icd) * unwillingness or inability to provide written informed consent * enrollment in, or intention to participate in, another clinical study during the course of this study * inaccessibility for follow-up at the study center * ventricular tachyarrhythmias associated with reversible causes * brugada syndrome, long qt and hypertrophic cardiomyopathy (hcm) patients * other electrical implantable devices (neurostimulators, etc.) * mechanical tricuspid valve

Keywords: atp thachy fvt
a study in participants with moderate to severe psoriasis (uncover-3)

Conditions: Psoriasis

Summary: this study will assess the safety and efficacy of ixekizumab (ly2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.


Eligibility criteria:
inclusion criteria: * presents with chronic plaque psoriasis based on a confirmed diagnosis of chronic psoriasis for at least 6 months prior to randomization * at least 10% body surface area (bsa) of psoriasis at screening and at randomization * static physician global assessment (spga) score of at least 3 and psoriasis area and severity index (pasi) score of at least 12 at screening and at randomization * candidate for phototherapy and/or systemic therapy * men must agree to use a reliable method of birth control or remain abstinent during the study * women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment exclusion criteria: * pustular, erythrodermic, and/or guttate forms of psoriasis * history of drug-induced psoriasis * prior use of etanercept * clinically significant flare of psoriasis during the 12 weeks prior to randomization * concurrent or recent use of any biologic agent * received non-biologic systemic psoriasis therapy or phototherapy (including psoralens and ultraviolet a \[puva\], ultraviolet b \[uvb\]) within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization * cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to randomization and during the study * have participated in any study with interleukin 17 (il-17) antagonists, including ixekizumab * serious disorder or illness other than plaque psoriasis * serious infection within the last 3 months * breastfeeding or nursing (lactating) women
central blood pressure in adolescents and young adults

Conditions: Healthy; Hypertension

Summary: this study aims to investigate in adolescents and young adults: * the 24h diurnal variation of ambulatory central blood pressure * the association of central compared to peripheral blood pressure with indices of asymptomatic target-organ damage


Eligibility criteria:
inclusion criteria: * adolescents and young adults (age range 12-25 years) exclusion criteria: * subjects with any acute or significant chronic disease, with evidence of secondary hypertension, or on regular drug treatment will be excluded

Keywords: central blood pressure ambulatory blood pressure monitoring target-organ damage adolescents and young adults
effect of skin-to-skin contact on interaction and parents' sleep

Conditions: Sleep Quality; Communication; Stress Reaction

Summary: this study evaluates the effect of a late intervention of continuous skin-to-skin contact (ssc) in the neonatal intensive care unit (nicu). half of the participants will receive the intervention and the other half will receive standard care.

the intervention is based on a method developed to facilitate closeness and human touch between parents and preterm infants in neonatal intensive care. continuous skin-to-skin contact (ssc) means, in this study, that the late preterm infant is cared for skin-to-skin on the parents' chest, instead of in a heating-bed, 24 hours a day. the parents will take turns to care for the infant in ssc.

Eligibility criteria:
inclusion criteria: * parents staying at the nicu with a single preterm infant born \<33 weeks of gestation * the family should have been transferred to family-room from intensive care * swedish speaking parents exclusion criteria: * infants with major congenital malformation, * infants with intraventricular hemorrhage grade iii-iv * infants with chromosome defect that could affect the infant´s ability to interact. * parents with sleeping disorder * parents with psychiatric problem or drug use.
traveler's diarrhea (td) automated process

Conditions: Prevention of Travelers' Diarrhea

Summary: to evaluate and compare the immune responses and safety following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of e. coli (lt) patches or placebo patches.


Eligibility criteria:
inclusion criteria: * healthy adult males or females, 18-64 years of age (inclusive) at the planned start of the study (first vaccination on day 0) * signed informed consent * women who are not post-menopausal or surgically sterile must have a negative serum/urine pregnancy test at screening and within 24 hours of each vaccination with understanding (through informed consent process) to not become pregnant and to employ an effective form of birth control for the duration of the study. acceptable forms of birth control are: abstinence, hormonal contraceptives (oral, injectable, implant, patch, ring), double-barrier contraceptives (condom or diaphragm, with spermicide), and iud. exclusion criteria: * laboratory abnormalities \[as determined by the toxicity grading scale (grade 1 4)\] at laboratory screening * abnormalities at physical examination \[as determined by the toxicity grading scale (grade 1-4)\] * known allergies to any component of the vaccine * known allergies to adhesives * participated in research involving investigational product within 30 days before planned date of first vaccination or within 90 days after first vaccination * donated blood or blood products such as plasma within 30 days prior to planned date of first vaccination or within 90 days after first vaccination * ever received investigational enterotoxigenic e. coli, lt, or lt (r192g) or nasalflu, berna biotech, ltd * ever received cholera toxin or vaccine (e.g. orochol™, dukoral™) * history of diarrhea while traveling in a developing country within the last year * history of abdominal surgery (excluding c-section, hysterectomy, cosmetic surgery, liposuction, appendectomy, cholecystectomy, ventral hernia repair, and other surgeries not pertaining to gastrointestinal problems) or history of, or recent acute gastrointestinal illness * positive serology for hiv-1, hiv-2, hbsag, or hcv * medical history of acute or chronic skin disease at vaccination area(s) * active skin allergy * signs of acute skin infection, sunburn or skin abnormalities at the vaccination area(s) including fungal infections, severe acne, or active contact dermatitis, or a history of keloid formation * excessively hirsute and unwilling to clip hair at the vaccination area(s) * visible tattoos or marks (tattoos/scars) at the vaccination area(s) that would prevent appropriate dermatologic monitoring of the vaccination site(s) * fever greater than or equal to 38.0°c (100.4°f) at the time of planned vaccination * women who are pregnant or breastfeeding * acute illness at screening and unresolved at time of planned vaccination * employee of the investigational site
efficacy of first time anterior shoulder decision tool

Conditions: Shoulder Dislocation

Summary: this study is a randomized controlled trial using duke patients to test, compared to the standard of care, a questionnaire and statistical model used to determine how patient preference regarding shoulder pain, physical limitations, physical therapy, recovery period, prognosis, and cost impact choice of surgical versus non-surgical intervention. phase 1 of this study is the initial testing of the instrument and involves a small group of up to 10 individuals who will partake in one-on-one interviews while completing the shoulder injury survey to provide feedback. in phase 2 of this study, 200 subjects will be randomized to receive either the decision tool or the standard information on shoulder dislocation

an anterior shoulder dislocation is a common problem for people between the ages of 15 to 35. recurrent instability is common and dependent on age and gender. treatment options include surgical intervention and repair or non-surgical options that include intensive rehabilitation. level i evidence suggests early surgical repair can significantly reduce the risk of recurrent instability. the risk of arthritis is increased with multiple dislocation episodes. traditionally, the combination of 1) history and physical exam performed by the provider, 2) clinical and diagnostic tools to assess the extent of injury and impact on physical activity, and 3) patient-voiced preference has guided the selection of an optimal solution for an individual patient. when providing a recommendation to individual patients and their unique circumstances, the health care provider may gather patient preferences on factors such as desire to avoid pain, chance of recurrent shoulder dislocation, time needed for rehabilitation and physical therapy, and operative versus non-operative costs. surgical and non-surgical options have distinct differences in these outcomes. when combined, the interaction between these variables creates important tradeoffs of risks and benefits for each option. no studies have been conducted to determine the objective weight of these different dimensions of patient preferences and how they might guide the provider-patient conversation. conjoint analysis is a statistical method that seeks to quantify the relative importance of various aspects of the decision-making process, such as cost or probability of repeat injury as described above. combined with a validated survey tool, conjoint analysis of patient preferences in shoulder repair can assist the physician in recommending a patient-centered option.

Eligibility criteria:
inclusion criteria: - shoulder dislocation exclusion criteria: * prior surgery for shoulder stabilization * inability to complete enrollment forms
long-term follow-up study for patients from avxs-101-cl-101

Conditions: Spinal Muscular Atrophy 1

Summary: this is a long term, safety follow up study of patients in the avxs-101-cl-101 gene replacement therapy clinical trial for sma type 1 delivering onasemnogene abeparvovec-xioi. patients will roll over from the parent study into this long-term study for continuous safety monitoring for up to 15 years.

this is a long term, safety follow up study of patients in the avxs-101-cl-101 gene replacement therapy clinical trial for sma type 1 delivering onasemnogene abeparvovec-xioi. patients will roll over from the parent study into this long-term study for continuous safety monitoring for up to 15 years. the last visit of the parent study or early discontinuation from the parent study may serve as the visit at which the informed consent form process is conducted for the avxs 101-lt-001 long term follow-up safety study. patients will return annually for follow up study visits for five (5) years, and then will be contacted via phone annually for ten (10) years. additionally, patient record transfers from their local physician and/or neurologist will be requested in conjunction with the annual study visits and phone contacts for review by the investigator. if the patient is unable to return to the original investigative site, the sponsor will arrange with the patients' local established physician to serve as an additional investigator to conduct the required assessments. this clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (that is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(a) of the public health service act and 42 cfr 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the public health service act or 42 cfr 11.24 and 11.44.).

Eligibility criteria:
inclusion criteria: 1. patient who received onasemnogene abeparvovec-xioi in the avxs-101-cl-101 gene replacement therapy clinical trial for sma type 1. 2. parent/legal guardian willing and able to complete the informed consent process, comply with study procedures and visit schedule. exclusion criteria: 1. parent/legal guardian unable or unwilling to participate in the long term follow up safety study.
pharmacotherapy for alcohol dependence in convicted drinking drivers

Conditions: Alcohol Dependence

Summary: this pilot study will explore the ways to link ontario's remedial system for convicted drinking drivers to medical intervention, assess the receptiveness of the back on track client population to effective medical interventions, and assess the feasibility of a full-scale trial of pharmacotherapy for convicted drinking drivers.

many individuals with alcohol dependence do not receive treatment, despite effective treatments being available. a significant healthcare challenge is to find ways to bring people who have alcohol dependence into treatment programs. drinking drivers are a group that has been shown to have high rates of alcohol dependence. in ontario, all convicted drinking drivers who want to obtain a drivers license must complete ontario's remedial program for convicted drinking drivers called back on track (bot). in this program, those with more serious alcohol-related problems are assigned to a group treatment program. while it is likely that many of the individual in this group are experiencing alcohol dependence, currently there is no formal linkage to any medical services for these problems. in this study, the investigators will provide those in the bot treatment group with information about a 24-week study assessing the effectiveness of naltrexone vs. placebo. this study will also assess the feasibility and level of interest among this population to obtain treatment for alcohol dependence.

Eligibility criteria:
inclusion criteria: * male or females - 18 years or older * been convicted of drinking driving and allocated to either the education or the treatment group of the bot program * meet criteria for alcohol dependence using the scid-iv * consume more than 14 drinks (female) or 21 drinks (male) per week with a minimum of 2 heavy drinking days (≥ 4 drinks for females and ≥ 5 drinks for males) during a consecutive 30-day period within the 90 days prior to the baseline evaluation * willing to receive pharmacotherapy for their alcohol dependence * seeking abstinence from alcohol as their main goal exclusion criteria: * history of other substance use (other than nicotine or cannabis) by dsm-iv criteria in the last 90 days (6 months for opiate abuse) * positive urine drug screen * psychiatric disorder requiring medication * unstable medical condition requiring immediate investigation or treatment * pregnancy or lactation

Keywords: back on track convicted drinking drivers naltrexone alcohol dependence
risperidone augmentation therapy in patients who have failed or only partially responded to a trial of antidepressant

Conditions: Major Depression

Summary: the purpose of this study is to assess the safety and efficacy of risperidone augmentation in patients who have failed to respond or only partially responded to an adequate trial of an antidepressant.

specific aims: the goal of this study was to assess the safety and efficacy of risperidone augmentation in patients with major depression who failed to respond, or only partially responded, to an adequate trial of an antidepressant medication. patients who met this criteria received adjunctive risperidone (1- 3 mg.) for an additional four-week treatment trial. subject population: a total sample of 84 patients completed the study at two sites (rhode island hospital/brown university, n=42, emory university, n=42). methods/design: patients who met criteria for unipolar depression and failed to respond, or partially responded, to an adequate trial of antidepressant medication were randomized to risperidone or a placebo for an additional 4 week treatment trial while continuing on the same dose of their antidepressant medication. randomization was at a 2:1 ratio of risperidone to placebo. data analysis: patient outcome (recovery status) of the two treatment conditions were compared using a madrs rating \< 10 to denote remission while improvement was defined as a 50% decrease from baseline to end of study. odds ratio were examined to see if risperidone augmentation significantly affected the chance of recovery from depression at the end of 4 weeks of treatment.

Eligibility criteria:
inclusion criteria: * patients with major depression or partially remitted depression * currently receiving an adequate trial of an antidepressant exclusion criteria: * diagnosis of bipolar i or bipolar ii disorder * psychotic features * substance dependence or abuse in the past three months